No abstract available.
Asthma* ; Theophylline*

No abstract available.
Asthma* ; Theophylline*

Preparation of theophylline microcapsule by the coacervation - phase seperation method. Theophylline microcapsule has been prepared by coacervation - phase seperation, using ethyl cellulose as the coating material. Ethyl cellulose sustanined significally the release of theophylline from microcapsule. Microcapsule has been used for preparation of theophylline sustained - release tablet.
Theophylline ; Capsules

The theophylline microcapsule has been prepared by spray-drying technique, using ethyl cellulose as the coating material. Ethyl cellulose sustained significally the release of theophylline from microcapsule has been used for preparation of theophylline sustained-released tablet.
Theophylline ; Capsules

No abstract available.
Asthma* ; Humans ; Prednisolone* ; Theophylline*

BACKGROUND: We evaluated the Vitros 950 (Johnson & Johnson Clinical Diagnostics, Inc., NY, USA) in the measurement of digoxin and theophylline levels and compared its results to those of the TDxFLx II (Abbott Laboratories, IL, USA) used for therapeutic drug monitoring (TDM) world-widely in order to assess the utility of the Vitros 950 as a TDM instrument. METHODS: From June 1997 to August 1997, 125 and 135 candidates for TDM were randomly chosen to measure digoxin and theophylline, respectively, using the Vitros 950 and TDxFLx II. The relationship between its results and those of TDxFLx II were determined. The within-run and between-run precisions of the Vitros 950 were determined using two controls (Vitros Performance Verifier I and II; J & J Clinical Diagnostics, Inc., NY, USA). The high-concentration control (Vitros Performance Verifier II) was diluted in Vitros 7% BSA to 5 dilutions. And linearity for quantitative analysis of digoxin and theophylline were determined. RESULTS: The coefficients of variation (CV) for the within-run of the Vitro 950 were 0.8% - 4.4%. And the CV for between-run precision of the Vitro 950 were 1.7% - 12.3%. The linearity of digoxin and theophylline were relatively good. The correlations (r) of digoxin and theophylline levels with those determined by the Abbott TDxFLx II were 0.95 and 0.93, respectively (P <0.001). CONCLUSIONS: The recently developed dry slide method of the Vitros 950 proves to good precision and linearity for quantitative analysis of digoxin and theophylline. Its results correlate well with those of the TDxFLx II. The Vitros 950 does not require an elaborate preparatory protocol for the sample, and is easy to use and maintain.So it is considered a highly feasible instrument for stat test.
Digoxin* ; Drug Monitoring ; Theophylline*

Theophylline tablets with release action (Theo KD) was tested in dosage 100mg x 2 tablets a time each 12 hours for asthma patients, and was compared to 100mg THEOSTAT tablet with release action of Laboratoiries INAVA (France). Results: Theo KD was suitable in the treatment of 2 0r 3 degree asthma. ADRs were minor and temporary. No one stopped treatment due to ADRs
Theophylline ; Tablets ; Chemistry

No abstract available.
Ciprofloxacin* ; Enoxacin* ; Humans* ; Metabolism* ; Theophylline*

The study conducted on bronchial asthmatic patients treated at Allergic Clinic in Bach Mai Hospital. The patients treated by theophylline pill acting within 12 hours, manufactured by Hanoi College of Pharmacy combined with Central Pharmaceutical Factory No. 2, used single-blind, controlled method. The patients used 200mg dose, twice in day (8 a.m and 8 p.m), separated from each other 12 hours. Results: The change of respiratory functions are good, both groups are more than 15 percentage
Theophylline ; Clinical Chemistry Tests ; Tablets

BACKGROUND AND OBJECTIVE: The knowledge about the effects of the nebulized B2-agonist on serum potassium is limited. We aimed to assess the possible hypokalemia following nebulization of salbutamol. METHOD: Seven patients(mean age 60 +- 7.1years) with acute exacerbated asthma were treated with salbutamol nebulization(5mg nebulization at 1 hour interval, 3 times) without concomitant use of steroid or other bronchodilator such as theophylline. RESULTS: There was a significant increase in FEV1, from 46.41+-25.91% at baseline to 62.86+-22.38% at 3 hours after treatment. Serum potassium concentration was significantly decreased, from 3.93+-0.58mEq/L at baseline to 3.41+-0.62mEq/L and 3.46+-0.53mEq/L at 1 hour and 3 hours after third nebulization, repectively. There was a significant prolongation of the QTc interval in EKG from 454.36+-27.07msec at baseline to 479.41+-35.64msec and 505.09+-58. 69msec at 1 hour and 3 hours after third nebulization, respectively. Serum salbutamol concentration was 4.18+-3.39ng/ml at baseline, and increased to 7.69+-6.94ng/ml and 9.84+10.34ng/ ml at 1 hour and 3 hours after treatment, respectively. Magnitude of the hypokalemia and the degree of prolongation of the electrocardiographic QTc interval were significantly correlated with the level of serum salbutamol concenturation. CONCLUSION: The results suggest that cardiac complication could develop due to hypokalemia during repeated salbutamol nebulization. Caution should be done in monitoring of serum potassium concentration when using nebulized salbutamol repeatedly for the treatment of acute exacerbated bronchial asthma.
Albuterol* ; Asthma ; Electrocardiography ; Hypokalemia ; Potassium* ; Theophylline